Pathological complete response in neoadjuvant treatment of breast cancer (Q38366388)

2 September 2017

Pathological complete response in neoadjuvant treatment of breast cancer (English)

1 reference

2 September 2017

1 reference

Patricia Cortazar

1

1 reference

PubMed ID

25727556

2 September 2017

Charles E Geyer

series ordinal

2

1 reference

2 September 2017

2 March 2015

1 reference

Annals of Surgical Oncology

2 September 2017

1 reference

2 September 2017

22

1 reference

2 September 2017

5

1 reference

2 September 2017

1441-1446

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-015-4404-8

2 September 2017

0 references

cites work

Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4404-8

10.1245/S10434-015-4404-8

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

25727556

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25727556